Kobayashi Pharmaceutical Co (KOY) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Kobayashi Pharmaceutical Co €10.66, price €38.00, upside -72.0%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
In Frankfurt, only 1 of the last 21 trading days (30 days) had any turnover. On the other days the price is an indicative quote without trading, so we do not list this stock in the radar. It stays reachable through search.
KPBroad dataSep 30, 2026
Kobayashi Pharmaceutical Co
KOY · F
Stretched ValuationStrong overvaluation with only moderate quality.
Watch Kobayashi Pharmaceutical Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 30, 2026.
How to read this chart
60‑month range €26.81 – €74.13 · fair‑value band €9.98 – €10.66 · the €38.00 price screens above the €10.66 fair value. Dashed = 300-day average. As of Sep 30, 2026.
Follow Kobayashi Pharmaceutical Co in your weekly email
Every Wednesday you see whether Kobayashi Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally.
Show more
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Stock analysis
Kobayashi Pharmaceutical Co (KOY) currently trades at €38.00, while our model-based Fair Value estimate is €10.66, 72.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €16.84 per share, and 0 of the 23 models we run sit above the €38.00 price.
Bear case: the Earnings-Based group reads lowest at €3.18, and 23 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: €9.98 (bear) to €10.66 (bull), the price of €38.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Kobayashi Pharmaceutical Co reported revenue of ¥166B in FY2025 versus ¥155B in FY2021, a compound +1.6%/yr. Reported net income was ¥3.7B in FY2025, compounding −34.4%/yr from FY2021.
Key figures
Market cap €2.8B · P/E ratio 316.7 · P/S ratio 6.99 · EPS (TTM) €0.1200 · Dividend yield 1.5% · Net margin 2.2% · Return on equity 0.8% · Return on assets (EBIT) 9.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −29% fair-value upside, at −72%, KOY screens richer than that median.
Fair Value models
Bear €9.98Fair Value €10.66Bull €10.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic). Over 10 years: +1.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−26.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−27.5%
Dividend (yield on the price)1.5%
Profit margin 2018 to 2023 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 15%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +14.8% a year for the price and +1.7% for the forecasts.
Compare Kobayashi Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 240 stocks
Beats the industry median on 0/14 measures
Overall it trails its industry peers.
Valuation
Quality Score57 · Below median
Fair Value upside−71.8% · Bottom 25%
Profitability
Return on equity (TTM)0.8% · Below median
Return on assets2.5% · Below median
Net margin (TTM)1.0% · Below median
Operating margin (TTM)2.3% · Below median
Growth and dividend
Revenue growth1.8% · Below median
Dividend yield (TTM)1.5% · Bottom 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/E (TTM)316.7× · Priciest 25%
P/B2.37× · Pricier than median
P/S (TTM)2.98× · Priciest 25%
P/FCF43.1× · Priciest 25%
EV/EBITDA22.3× · Priciest 25%
PEG6.66× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)9· sector 15
PAST (return on equity)3· sector 28
HEALTH (low debt)0· sector 98
DIVIDEND (yield)29· sector 54
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kobayashi Pharmaceutical Co Fair Value". https://www.fairvalue-calculator.com/stock/KOY
Frequently asked questions
Is Kobayashi Pharmaceutical Co (KOY) overvalued or undervalued?
As of Sep 30, 2026, our model estimates a fair value of €10.66 versus a price of €38.00, about −72% upside (overvalued).
What is the fair value of KOY?
Our model-based fair value for Kobayashi Pharmaceutical Co is €10.66 (as of Sep 30, 2026), built from audited fundamentals. The current price: €38.00.
What is the quality score of KOY?
Kobayashi Pharmaceutical Co has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kobayashi Pharmaceutical Co (KOY)?
Our model-based price target is the fair value of €10.66 (as of Sep 30, 2026) from 23 valuation models. Cautious scenario €9.98, optimistic scenario €10.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Kobayashi Pharmaceutical Co stock forecast for 2026?
Our models put fair value at €10.66, about −72% upside versus a price of €38.00 (overvalued). Cautious scenario €9.98, optimistic scenario €10.66. The calculation is refreshed regularly with new filings.
What is the revenue of Kobayashi Pharmaceutical Co (KOY)?
Kobayashi Pharmaceutical Co reported trailing-twelve-month revenue of about ¥167B (latest available figure, as of Sep 30, 2026).
Does Kobayashi Pharmaceutical Co pay a dividend?
Kobayashi Pharmaceutical Co currently shows a dividend yield of about 1.47% relative to its recent price (as of Sep 30, 2026).
What growth is priced into Kobayashi Pharmaceutical Co (KOY)?
For today's price to be fair in a discounted-cash-flow model, Kobayashi Pharmaceutical Co would have to grow free cash flow by +17.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. As of Sep 30, 2026.
What discount rate (WACC) does the fair value of KOY use?
Our models discount Kobayashi Pharmaceutical Co at 8.3 %: a base by market capitalisation (mid), damped by beta 0.27, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kobayashi Pharmaceutical Co that is +17.2 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Kobayashi Pharmaceutical Co (KOY) delivered so far?
Over the past 5 years revenue at Kobayashi Pharmaceutical Co grew +2.0 % a year. The price currently implies +17.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kobayashi Pharmaceutical Co (KOY) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into Kobayashi Pharmaceutical Co (+17.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kobayashi Pharmaceutical Co (KOY)?
The free-cash-flow yield on the price is 2.31 %: that much free cash flow Kobayashi Pharmaceutical Co produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kobayashi Pharmaceutical Co (KOY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kobayashi Pharmaceutical Co it is €10.66 per share (as of Sep 30, 2026), against a price of €38.00. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Kobayashi Pharmaceutical Co stock overvalued or undervalued in 2026?
As of Sep 30, 2026, KOY trades above its calculated fair value: price €38.00, fair value €10.66, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KOY?
No. The price is what the market pays today (€38.00); the fair value is what the company's own numbers justify (€10.66). For Kobayashi Pharmaceutical Co the two are €27.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kobayashi Pharmaceutical Co worth?
The market values Kobayashi Pharmaceutical Co at about €2.8B (market capitalisation, as of Sep 30, 2026). Per share that is €38.00; our models calculate a fair value of €10.66 per share.
What do the bullish and bearish scenarios say about KOY?
Our models span a range for Kobayashi Pharmaceutical Co: cautious scenario €9.98, base €10.66, optimistic €10.66 per share (as of Sep 30, 2026, price €38.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KOY?
Kobayashi Pharmaceutical Co trades at a price-to-earnings ratio of 316.7 (as of Sep 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €10.66 is built from several models across several years. Other multiples: PEG 6.7, P/B 2.4, P/S 3.0, EV/EBITDA 22.3.
What is the PEG ratio of KOY?
The PEG ratio of Kobayashi Pharmaceutical Co is 6.66 (P/E divided by earnings growth, as of Sep 30, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Kobayashi Pharmaceutical Co (KOY)?
Balance-sheet figures for Kobayashi Pharmaceutical Co (as of Sep 30, 2026): return on equity 0.8%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is KOY from its 52-week high?
Kobayashi Pharmaceutical Co trades at €38.00, about 3% below its 52-week high of €39.00 and 41% above the low of €26.86 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of €10.66 is for.
Which stocks are comparable to Kobayashi Pharmaceutical Co?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, The Estée Lauder Companies Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kobayashi Pharmaceutical Co stock attractive at the current price?
The data as of Sep 30, 2026: price €38.00, calculated fair value €10.66 (−72%), Quality Score 57/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KOY calculated?
We run Kobayashi Pharmaceutical Co through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €10.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Kobayashi Pharmaceutical Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kobayashi Pharmaceutical Co (KOY)?
The closing price on Oct 1, 2026 was €38.00. Our model-based fair value is €10.66, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kobayashi Pharmaceutical Co right now?
The price sits above even our optimistic bull case (€10.66). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (€9.98 to €10.66), unusually little disagreement for a valuation.
Key figures of Kobayashi Pharmaceutical Co
How large is the market capitalisation of Kobayashi Pharmaceutical Co (KOY)?
The market capitalisation of Kobayashi Pharmaceutical Co is €2.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kobayashi Pharmaceutical Co (KOY)?
The price-to-sales ratio of Kobayashi Pharmaceutical Co is 6.99 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kobayashi Pharmaceutical Co (KOY)?
Earnings per share at Kobayashi Pharmaceutical Co are €0.1200 (price ÷ EPS = P/E 316.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kobayashi Pharmaceutical Co (KOY)?
The dividend yield of Kobayashi Pharmaceutical Co is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kobayashi Pharmaceutical Co (KOY)?
The net margin of Kobayashi Pharmaceutical Co is 2.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kobayashi Pharmaceutical Co (KOY)?
The return on equity (ROE) of Kobayashi Pharmaceutical Co is 0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kobayashi Pharmaceutical Co (KOY)?
On an EBIT basis the return on assets of Kobayashi Pharmaceutical Co is 9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kobayashi Pharmaceutical Co (KOY)?
The operating margin of Kobayashi Pharmaceutical Co is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kobayashi Pharmaceutical Co (KOY)?
Revenue at Kobayashi Pharmaceutical Co is growing +1.8% versus a year earlier (3y avg −0.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kobayashi Pharmaceutical Co (KOY)?
Earnings per share at Kobayashi Pharmaceutical Co are growing −93.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Kobayashi Pharmaceutical Co in the live analysis
One click puts Kobayashi Pharmaceutical Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
